Filing Flows › Akebia Therapeutics (AKBA) › Stock forecast & fair value
Akebia Therapeutics (AKBA) stock forecast and price target
Akebia Therapeutics (AKBA) trades at $0.40. 6 analysts' median price target is $4.00 (+897%), from $1.00 to $6.00.
Akebia Therapeutics' latest quarter
Akebia Therapeutics, Q3 2026: revenue $36.9M (-37% year over year), operating margin -31.1%, net loss $14.4M, operating cash flow $2.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for AKBA stock?
The median of 6 analysts' 12-month targets is $4.00, +897% from $0.40; the range is $1.00 to $6.00. The average rating is strong buy.
Does Akebia Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 40% of the quarters on record.
Is AKBA stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.